OR51E2 activation results in anti-proliferative effect and metastasis in prostate cancer cells, anti-proliferative effect and melanogenesis in melanocytes and proliferation and metastasis in retinal pigment epithelial cells. Here, OR51E2 is linked to prostate carcinoma.